benserazide has been researched along with Hallucinations in 3 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Hallucinations: Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seven patients with idiopathic Parkinson's disease, aged 62 to 76 years, average duration of the disease approximately eleven years, suffering from severe hallucinosis and paranoid delusions of different degree, in whom conventional therapeutic strategies (administration of benzodiazepines and mild neuroleptics) had no antipsychotic effect, received clozapine, a non-classical highly potent neuroleptic, while blood count was strictly monitored." | 1.29 | Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. ( Helscher, RJ; Pinter, MM, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hattori, N | 1 |
| Pinter, MM | 1 |
| Helscher, RJ | 1 |
| Scholz, E | 1 |
| Dichgans, J | 1 |
1 review available for benserazide and Hallucinations
| Article | Year |
|---|---|
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].
Topics: Benserazide; Benzothiazoles; Catechols; Circadian Rhythm; Dementia; Dopamine Agonists; Drug Combinat | 2014 |
2 other studies available for benserazide and Hallucinations
| Article | Year |
|---|---|
Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease.
Topics: Aged; Benserazide; Blood Cell Count; Clozapine; Female; Hallucinations; Humans; Levodopa; Male; Midd | 1993 |
Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.
Topics: Aged; Antipsychotic Agents; Benserazide; Bromocriptine; Clozapine; Delusions; Dibenzazepines; Dose-R | 1985 |